

February 4, 2014

Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014

Conference Call Today at 5:00 p.m. Eastern

AUSTIN, Texas, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for 2013 and provided guidance for 2014. Net profit in 2013 was \$31.5 million, or \$0.70 per diluted share, compared to a net loss in 2012 of \$3.4 million, or \$0.08 per share.

"We are excited about what lies ahead for PTIE in 2014," said Remi Barbier, President & CEO. "We'll be watching the progress of REMOXY carefully over the next few quarters, as Pfizer has stated an intent to refile an NDA mid-2015. Any moves towards risk-reduction around this drug candidate may accelerate our corporate strategy to transition from purely an R&D company to a mix of R&D and product revenue. Based on the clinical and commercial profiles of REMOXY, and potential upside of our early-stage assets, I believe 2014 may be a pivotal year for us."

We expect net cash usage for 2014 may be approximately \$12 million, reflecting increased investment in early-stage assets. At December 31, 2013, cash and investments were \$49.8 million.

Financial Highlights for 2013

- Total revenue increased to \$41.1 million in 2013 from \$10.6 million in 2012, reflecting a previously disclosed amendment in our strategic alliance with Pfizer, Inc. In Q4 2013, we amended our strategic alliance with Pfizer and, as a result, recognized all remaining non-cash deferred revenue at the end of Q3 2013 as contract revenue during Q4 2013.
- We do not expect to have taxable income in 2013 because the related revenue was recognized for tax purposes in prior years.
- Research and development expenses decreased to \$4.9 million in 2013 from \$7.6 million in 2012, primarily due to lower
 cash compensation and non-cash stock-related compensation. Research and development expenses included non-cash
 stock-related compensation costs of \$1.3 million in 2013 and \$3.2 million in 2012.
- General and administrative expenses decreased to \$4.8 million in 2013 from \$7.2 million in 2012, primarily due to lower cash compensation and non-cash stock-related compensation. General and administrative expenses included non-cash stock-related compensation costs of \$1.8 million in 2013 and \$3.4 million in 2012.
- At December 31, 2013, cash and investments were \$49.8 million, compared to \$56.3 million at December 31, 2012. We have no debt.

ABOUT REMOXY

Our lead drug candidate, REMOXY[®], is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage common methods of tampering and misuse. Pfizer, Inc. (NYSE:PFE) is our exclusive, worldwide commercial partner for REMOXY (oxycodone) Extended-Release Capsules CII, except as to Australia and New Zealand.

REMOXY Deal Economics

- To date, we have received total cash payments of \$185 million in program fees and milestone payments under our strategic alliance with Pfizer.
- We are eligible to receive from Pfizer a \$15.0 million payment upon FDA approval of REMOXY.
- After the commercial launch of REMOXY by Pfizer, we will receive a royalty of 20% of net sales in the United States, except as to the first \$1.0 billion in cumulative net sales, which royalty is set at 15%. Outside the United States, the royalty rate is 10%.

- We will also receive from Pfizer a supplemental payment of 6.0% to 11.5% of net sales, depending on the range of total dollar sales in each year, covered by the strategic alliance. This supplemental payment is tied to the full amount of our financial obligations to Durect Corporation, our exclusive supplier of certain excipients in REMOXY.
- In October 2013, Pfizer returned to us all rights with respect to abuse-resistant formulations of three opioid drugs: hydrocodone, hydromorphone and oxymorphone. These drug assets now vest exclusively in us without any royalty or other obligation to Pfizer. We are free to develop and commercialize these assets on our own or with a licensee of our choice, and may do so without notice or approval from Pfizer. Investigational New Drug (IND) applications for all three drug assets are in place with FDA. We have not yet made a decision to develop or to out-license these three drug assets.
- All development and commercialization expenses around REMOXY are reimbursed or paid for by Pfizer.
- We retain commercial rights to REMOXY in Australia/New Zealand. We have not yet announced a market entry strategy for these territories.

Conference Call

Pain Therapeutics will host a conference call today at 5:00 p.m. Eastern time to discuss 2013 financial results, provide guidance for 2014 and to respond to questions.

<u>To participate in the conference call, please dial 1-877-407-9039</u> (within the U.S.) or 1-201-689-8470 (outside the U.S.) prior to the start of the call. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at www.paintrials.com. A playback of the call will be available for approximately 7 days after the live event. To access the playback, please dial 1-877-870-5176 (within the U.S.) or 1-858-384-5517 (outside the U.S.) and enter code 13575504.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit www.paintrials.com.

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the company's projected cash use for 2014; the progress of REMOXY over the next few quarters, future growth of early stage assets, expectations related to taxable income for 2013; potential future milestone payments; reimbursement of development expenses for REMOXY and supplemental payments and royalties based on revenue from REMOXY. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in obtaining regulatory approval of REMOXY and in development, testing and pursuit of regulatory approval of our other drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates; difficulties or delays in commercialization efforts with respect to our products, if any are approved for marketing, or failure of such products to gain market acceptance; the uncertainty of patent protection for our intellectual property or trade secrets; unanticipated additional research and development, litigation and other costs; the timing and receipt of funds from Pfizer; potential diversion of resources from the pursuit of development and commercialization of REMOXY; and the potential for abuse-resistant pain medications or other competing products or therapies to be developed by competitors and potential competitors or others. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.

- Financial Tables Follow -

PAIN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share amounts)

Three Months Ended Years Ended
December 31, December 31,

Total revenue 35,244 2,468 41,119 10,890 Operating expenses: Research and development 1,151 2,101 4,917 7,605 General and administrative 1,190 2,209 4,837 7,182 Total operating expenses 2,341 4,310 9,754 14,787 Operating income (loss) 32,903 (1,842) 31,365 (3,897) Interest and other income, net 39 46 106 451 Income (loss) before provision for (benefit from) income taxes 32,942 (1,796) 31,471 (3,446) Provision for (benefit from) income taxes (73) - (73) - (73) -		2013	2012 ⁽¹⁾	2013	2012 ⁽¹⁾	
Collaboration revenue — — 249 Total revenue 35.24 2.468 41.119 10.809 Operating expenses: — — 4.0119 7.605 Research and development 1.151 2.101 4.917 7.605 General and administrative 1.190 2.209 4.837 7.182 Total operating expenses 2.341 1.301 9.754 14.787 Operating income (loss) 3.2903 (1.822) 31.365 (3.897) Income (loss) before provision for (benefit from) income taxes 3.292 1.769 31.47 (3.466) Provision for (benefit from) income taxes 3.301 \$ (1.796) 31.54 \$ (3.607) Net income (loss) per share \$0.02 \$ (0.00) \$ (0.00) \$ (0.00) Net income (loss) per share \$0.02 \$ (0.00) \$ (0.00) \$ (0.00) Basic \$0.07 \$ (0.00) \$ (0.00) \$ (0.00) \$ (0.00) Basic \$0.00 \$ (0.00) \$ (0.00) \$ (0.00) \$ (0.0	Revenue:					
Total revenue	Program fee revenue	\$ 35,244	\$ 2,468	\$ 41,119	\$ 10,641	
Operating expenses: Control of the properties of the properti	Collaboration revenue			<u></u>	249	
Research and development 1,151 2,101 4,917 7,050 Geneal and administrative 1,190 2,208 4,837 7,182 Total operating expenses 2,341 4,310 9,754 14,787 Operating income (loss) 32,903 (1,842) 31,365 (3,897) Interest and other income, net 39 46 106 451 Income (loss) before provision for (benefit from) income taxes 27,31 − 31,471 (3,446) Net income (loss) \$3,015 \$ (1,796) \$31,544 \$ (3,466) Net income (loss) per share \$30,73 \$ (1,076) \$ (3,046) Basic \$0,73 \$ (0,04) \$ 0,70 \$ (0,08) Weighted-average shares used in computing net income (loss) per share \$ 45,062 \$ 44,903 \$ 45,007 \$ 4,4753 Diluted \$ 45,062 \$ 44,903 \$ 45,007 \$ 4,4753 Diluted \$ 45,062 \$ 44,903 \$ 45,002 \$ 44,753 CONDENSED BALANCE SHEETS Polymer developeration of the polymer developeration	Total revenue	35,244	2,468	41,119	10,890	
General and administrative 1,190 2,204 4,837 7,182 Total operating expenses 2,341 4,310 9,754 14,787 Operating income (loss) 32,903 (1,842) 3,365 (3,887) Interest and other income, net 39 46 106 451 Income (loss) before provision for (benefit from) income taxes (73) — √7,30 — Net income (loss) \$33,015 \$(1,796) \$3,1471 (3,466) Net income (loss) per share \$0.72 \$(0,00) \$0,008 \$0,009 \$0,008 Basic \$0.72 \$(0,00) \$0,700 \$0,008 Weighted-average shares used in computing net income (loss) per share \$45,059 \$44,903 \$45,000 \$44,753 Diluted \$0.00 \$45,862 \$44,903 \$45,000 \$44,753 CONDENSED BALANCE SHEETS \$45,059 \$44,903 \$45,000 \$44,753 Condense Selection of the provision of the provis	Operating expenses:					
Total operating expenses 2,341 4,310 9,754 14,787 Operating income (loss) 32,903 (1,842) 31,365 (3,897) Interest and other income, net 39 46 106 451 Income (loss) before provision for (benefit from) income taxes 32,942 (1,796) 31,471 (3,446) Provision for (benefit from) income taxes \$33,015 \$(1,796) \$31,544 \$(3,446) Net income (loss) \$33,015 \$(1,796) \$31,544 \$(3,446) Net income (loss) per share \$9,72 \$(0,04) \$0,70 \$(0,08) Weighted-average shares used in computing net income (loss) per share \$45,059 \$44,903 \$45,007 \$(0,08) Weighted-average shares used in computing net income (loss) per share \$45,069 \$44,903 \$45,007 \$44,753 Diluted \$45,069 \$44,903 \$45,007 \$44,753 CONDENSED BALANCE SHEETS \$243,802 \$44,903 \$45,000 \$45,000 CONDENSED BALANCE SHEETS \$49,803 \$45,000 \$6,000 \$6,000 <td>Research and development</td> <td>1,151</td> <td>2,101</td> <td>4,917</td> <td>7,605</td>	Research and development	1,151	2,101	4,917	7,605	
Operating income (loss) 32,903 (1,842) 31,365 (3,897) Interest and other income, net 39 46 106 451 Income (loss) before provision for (benefit from) income taxes 32,942 (1,796) 31,471 (3,446) Provision for (benefit from) income taxes \$3,3,015 \$(1,796) \$31,544 \$(3,446) Net income (loss) \$3,3,015 \$(1,796) \$31,544 \$(3,446) Net income (loss) per share \$3,072 \$(0,04) \$0.70 \$(0,08) Diluted \$0.72 \$(0,04) \$0.70 \$(0,08) Basic \$45,052 \$44,903 \$45,007 \$(0,08) Diluted \$45,862 \$44,903 \$45,007 \$44,753 CONDENSED BALANCE SHEETS December 1 CONDENSED BALANCE SHEETS December 3 December 3 10,120 December 3 20,120 10,120 December 3 20,120 10,120 10,120 10,120 10,	General and administrative	1,190	2,209	4,837	7,182	
Interest and other income, net income, net income (loss) before provision for (benefit from) income taxes 39 46 106 451 Income (loss) before provision for (benefit from) income taxes 32,942 (1,796) 31,471 (3,466) Provision for (benefit from) income taxes (33) \$ (1,796) \$ 31,544 \$ (3,466) Net income (loss) per share \$ 50.72 \$ (0,008) \$ 31,544 \$ (0,008) Basic \$ 0.72 \$ (0,004) \$ 0.70 \$ (0,008) Diluted \$ 50.72 \$ (4,900) \$ 45,007 \$ (0,008) Basic \$ 45,005 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,005 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,005 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,005 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,005 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 50,005 \$ 50,005 \$ 50,005 \$ 50,005 \$ 50,005 \$ 50,005 \$ 50,005 \$ 50,005	Total operating expenses	2,341	4,310	9,754	14,787	
Income (loss) before provision for (benefit from) income taxes 32,942 (1,796) 31,471 (3,446) Provision for (benefit from) income taxes (73) — (73) — Net income (loss) \$33,015 \$ (1,796) \$31,544 \$ (3,446) Net income (loss) per share \$0.73 \$ (0.04) \$ 0.70 \$ (0.08) Diluted \$0.72 \$ (0.04) \$ 0.70 \$ (0.08) Weighted-average shares used in computing net income (loss) per share \$ 45,059 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,862 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,862 \$ 44,903 \$ 45,008 \$ 44,753 CONDENSED BALANCE SHEETS December 3 Condenses December 3 \$ 44,903 \$ 45,007 \$ 44,753 Condenses December 3 December 3 <td colspan<="" td=""><td>Operating income (loss)</td><td>32,903</td><td>(1,842)</td><td>31,365</td><td>(3,897)</td></td>	<td>Operating income (loss)</td> <td>32,903</td> <td>(1,842)</td> <td>31,365</td> <td>(3,897)</td>	Operating income (loss)	32,903	(1,842)	31,365	(3,897)
Provision for (benefit from) income taxes (73) — (73) — Net income (loss) \$33,015 \$(1,796) \$31,544 \$(3,446) Net income (loss) per share \$0.73 \$(0.04) \$0.70 \$(0.08) Basic \$0.73 \$(0.04) \$0.70 \$(0.08) Weighted-average shares used in computing net income (loss) per share Basic \$45,059 \$44,903 \$45,007 \$44,753 Diluted \$45,862 \$44,903 \$45,208 \$44,753 CONDENSED BALANCE SHEETS Decembers CONDENSED BALANCE SHEETS Decembers Decembers Decembers Decembers Decembers Decembers Decembers Decembers <	Interest and other income, net	39	46	106	451	
Net income (loss) \$ 33,015 \$ (1,796) \$ 31,544 \$ (3,446) Net income (loss) per share \$ 0.73 \$ (0.04) \$ 0.70 \$ (0.08) Diluted \$ 0.72 \$ (0.04) \$ 0.70 \$ (0.08) Weighted-average shares used in computing net income (loss) per share \$ 45,059 \$ 44,903 \$ 45,007 \$ 44,763 Diluted \$ 45,862 \$ 44,903 \$ 45,007 \$ 44,763 Diluted \$ 45,862 \$ 44,903 \$ 45,007 \$ 44,763 CONDENSED BALANCE SHEETS December 3.1 2013 2012(¹¹) Assets Experiment assets S 49,838 \$ 56,254 Current assets \$ 49,838 \$ 56,254 Other non-current assets \$ 265 265 263 Total current assets \$ 50,103 56,507 Other non-current assets \$ 50,103 \$ 56,859 Liabilities and stockholders' equity Experiment liabilities \$ 1,086 \$ 1,290	Income (loss) before provision for (benefit from) income taxes	32,942	(1,796)	31,471	(3,446)	
Net income (loss) per share Basic \$ 0.72 \$ (0.04) \$ 0.70 \$ (0.08) Diluted \$ 0.72 \$ (0.04) \$ 0.70 \$ (0.08) Weighted-average shares used in computing net income (loss) per share \$ 45,059 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,862 \$ 44,903 \$ 45,007 \$ 44,753 CONDENSED BALANCE SHEETS December 3 2013 2012(¹) Assets Current assets S 49,838 \$ 56,254 Other current assets \$ 2013 2012(¹) Cash, cash equivalents and marketable securities \$ 49,838 \$ 56,254 Other current assets \$ 265 253 Total current assets \$ 50,103 56,507 Other non-current assets \$ 50,103 55,609 Current liabilities \$ 50,103 55,689 Liabilities and stockholders' equity Current liabilities \$ 1,802	Provision for (benefit from) income taxes	(73)	<u> </u>	(73)	<u> </u>	
Net income (loss) per share Basic \$0.73 \$(0.04) \$0.70 \$(0.08) Diluted \$0.72 \$(0.04) \$0.70 \$(0.08) Weighted-average shares used in computing net income (loss) per share \$45.059 \$44.903 \$45.007 \$44.753 Diluted \$45.862 \$44.903 \$45.007 \$44.753 CONDENSED BALANCE SHEETS December 3.4753 CONDENSED BALANCE SHEETS December 3.4553 Seq 5.4553 Seq 5.6553	Net income (loss)	\$ 33,015	\$ (1,796)	\$ 31,544	\$ (3,446)	
Basic Diluted \$ 0.73 b (0.04) b (0.04) b (0.08) b (0.08) \$ 0.072 b (0.04) b (0.04) b (0.08) \$ 0.08) b (0.08) b (0.08) Weighted-average shares used in computing net income (loss) per share \$ 45.059 b (44.903) b (44.903) b (44.753) b (44.753) b (1.04.753) \$ 44.903 b (44.753) b (44.753) b (1.04.753) b (1	` <i>'</i>					
Diluted \$0.72		\$ 0.73	\$ (0.04)	\$ 0.70	\$ (0.08)	
Weighted-average shares used in computing net income (loss) per share Basic \$ 45,059 \$ 44,903 \$ 45,007 \$ 44,753 Diluted \$ 45,862 \$ 44,903 \$ 45,208 \$ 44,753 CONDENSED BALANCE SHEETS December 31. 2013 2012 ⁽¹⁾ (Unaudited) Assets Current assets Cash, cash equivalents and marketable securities \$ 49,838 \$ 56,254 Other current assets 265 253 Total current assets 50,103 \$ 56,507 Other non-current assets 50,103 \$ 56,859 Total current sasets \$ 50,103 \$ 56,859 Liabilities \$ 1,086 \$ 1,290 Current liabilities \$ 1,801 9,999 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999		\$ 0.72				
Basic \$45,059 \$44,903 \$45,007 \$44,753 Diluted \$45,862 \$44,903 \$45,208 \$44,753 CONDENSED BALANCE SHEETS December 1 CONDENSED BALANCE SHEETS December 1 December 1 December 1 December 1 CONDENSED BALANCE SHEETS December 1 Sept 1		<u> </u>	(0.0.)		\(\psi\)	
Substitute		\$ 45.050	¢ 44 003	¢ 45 007	¢ 11 752	
CONDENSED BALANCE SHEETS December 31. December 31. Decemb						
December 3 Assets Current assets Cash, cash equivalents and marketable securities \$49,838 \$56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets 50,103 \$56,859 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999	Diluted	\$ 45,862	\$ 44,903	\$ 45,208	\$ 44,753	
Assets Current assets Cash, cash equivalents and marketable securities \$49,838 \$56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets 50,103 \$56,859 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity 2 50,103 \$56,859 Current liabilities \$1,086 \$1,290 Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities	CONDENSED BALANCE SHEETS					
(Unaudited) Assets Current assets \$49,838 \$56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets - 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999				December	31,	
(Unaudited) Assets Current assets \$49,838 \$56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets - 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999			-	2013	2012 ⁽¹⁾	
Assets Current assets \$49,838 \$56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets — 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion — 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999						
Current assets \$ 49,838 \$ 56,254 Other current assets 265 253 Total current assets 50,103 56,507 Other non-current assets - 352 Total assets \$ 50,103 \$ 56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$ 1,086 \$ 1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999	Assets			(=::===::==)		
Other current assets 253 Total current assets 50,103 56,507 Other non-current assets — 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion — 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999						
Other current assets 253 Total current assets 50,103 56,507 Other non-current assets — 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion — 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999	Cash, cash equivalents and marketable securities			\$ 49.838	\$ 56.254	
Total current assets 50,103 56,507 Other non-current assets — 352 Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion — 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities 1,801 9,999						
Other non-current assets—352Total assets\$ 50,103\$ 56,859Liabilities and stockholders' equityCurrent liabilitiesAccounts payable and accrued development expenses\$ 1,086\$ 1,290Deferred program fee revenue - current portion—7,832Other accrued liabilities715877Total current liabilities1,8019,999Non-current liabilities1,8019,999			-	50.103		
Total assets \$50,103 \$56,859 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities				_		
Liabilities and stockholders' equity Current liabilities Accounts payable and accrued development expenses Deferred program fee revenue - current portion Other accrued liabilities Total current liabilities Non-current liabilities			-	\$ 50.103		
Current liabilities Accounts payable and accrued development expenses Deferred program fee revenue - current portion Other accrued liabilities Total current liabilities Non-current liabilities Standard St			=	, , , , , , , , , , , , , , , , , , , 		
Accounts payable and accrued development expenses \$1,086 \$1,290 Deferred program fee revenue - current portion - 7,832 Other accrued liabilities 715 877 Total current liabilities 1,801 9,999 Non-current liabilities						
Deferred program fee revenue - current portion — 7,832 Other accrued liabilities — 715 877 Total current liabilities — 1,801 9,999 Non-current liabilities				\$ 1 086	\$ 1 290	
Other accrued liabilities Total current liabilities 1,801 9,999 Non-current liabilities				Ψ 1,000		
Total current liabilities 1,801 9,999 Non-current liabilities	·			715		
Non-current liabilities			-			
				1,001	0,000	
				_	33 287	
				_	437	
			-	1 801	43,723	
Stockholders' equity			-	1,001	70,120	

45

152,363

(104,107)

48,302

45

148,738

(135,651)

13,136

Common stock

Additional paid-in-capital

Total stockholders' equity

Accumulated deficit

Accumulated other comprehensive income

(1) Derived from the Company's annual financial statements as of December 31, 2012, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

CONTACT: For More Information Contact:

Peter S. Roddy

Vice President and Chief Financial Officer

Pain Therapeutics, Inc.

proddy@paintrials.com

(512) 501-2450

Barbara Ryan

FTI Consulting

Barbara.ryan@fticonsulting.com

(212) 850-5679